Member
Posts (7)
What a nice bear trap!
https://allsci.com/news/clinical-trials/tau-gene-therapy-alzheimers-voyager-advances/
Voyager registers first-in-human trial of tau-silencing gene therapy VY1706 in Alzheimer’s
A positive post-earnings signal for $VYGR: H.C. Wainwright reaffirmed its Buy rating on Voyager Therapeutics on Monday following the Q2 results.
A positive post-earnings signal for $VYGR: H.C. Wainwright reaffirmed its Buy rating on Voyager Therapeutics on Monday following the Q2 results.
$VYGR After looking at the weekly chart from several different angles (Volume Profile, VWAP, Donchian and Keltner Channels), I keep coming back to the same conclusion.
Around $3 looks like a major accumulation zone. Price has repeatedly tested this area without breaking down, while volatility has compressed to levels that often precede a significant move.
The next real volume wall doesn’t appear until roughly $4.20–4.50. If buyers can push through that range, the chart opens up considerably with much less historical resistance above.
To me, this no longer looks like a stock in a prolonged downtrend. It looks like a stock building a base before its next major move. The technical picture is tightening, while the fundamental catalysts are still ahead.
If the upcoming clinical and partnership news delivers, I believe the upside could be far greater than the downside from current levels. Time will tell, but this is one of the more asymmetric biotech setups I’ve seen in a while.